RCM
REGN icon

Radnor Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Radnor Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-700
Closed -$414K – 238
2022
Q2 		$414K Hold
700
– – 0.11% 172
2022
Q1 		$489K Buy
700
+60
+9% +$38K 0.12% 165
2021
Q4 		$404K Buy
640
+200
+45% +$123K 0.1% 179
2021
Q3 		$266K Buy
+440
New +$273K 0.16% 81

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Radnor Capital Management's REGN Position: Q3 2022 in Review

Radnor Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2022, closing a stake of 700 shares — an estimated $414K sold.

Radnor Capital Management first reported a position in REGN in Q3 2021 and held it in 4 quarters. The position peaked at $489K in Q1 2022. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

  • Radnor Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Radnor Capital Management sold 700 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $414K.
  • Radnor Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • Radnor Capital Management's Regeneron Pharmaceuticals position peaked at $489K in Q1 2022.
  • 1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on Radnor Capital Management's 13F filing for Q3 2022, filed 12 Oct 2022.